Introduction: Serum chromogranin A (CgA) is used as a tumor marker for neuroendocrine tumors (NETs).
Aim(s): Assessment of the sensitivity of the tumor marker CgA in NETs of the gastroenteropancreatic system.
Materials and methods: CgA levels were measured in serum samples from 110 patients with midgut and pancreatic NETs (n=62 and n=48, respectively) in a retrospective single-center series during clinical routine in the years 2000 – 2009. For CgA determination, a commercially available immunoradiometric assay (IRMA, CIS-Bio) was used (""cutoff"" < 98 ng/ml).
Conference: 7th Annual ENETS Conference (2010)
Presenting Author: Dr. Svenja Nölting
To read results and conclusion, please login ...
Further abstracts you may be interested in
Introduction: CgA is the most important biochemical marker for evaluation of NETs. Different assays with different accuracy exist.
Conference: 9th Annual ENETS Conference (2012)
Presenting Author: Lise Brehm Høj
Introduction: Chromogranin A (CgA) is the most important general tumor marker used in the diagnosis and follow-up of patients with neuroendocrine tumors (NET). CgA assays may have different sensitivities, which is of importance for the clinical diagnosis and handling of NET patients.
Conference: 10th Annual ENETS Conference 2013 (2013)
Presenting Author: Dr. Henning Grønbæk
Introduction: Although Chromogranin A (CgA) is known as a useful marker for pancreatic neuroendocrine tumors (pNET) in the West, the usefulness of CgA in Japanese patients with pNETs is unclear.
Conference: 11th Annual ENETS Conference 2014 (2014)
Presenting Author: Masayuki Hijioka
Introduction: Currently, serum chromogranin A (CgA) is used as a biomarker for pancreatic neuroendocrine tumors (pNET); however, oral use of a proton pump inhibitor (PPI) and renal impairment can affect CgA.
Conference: 14th Annual ENETS conference 2017 (2017)
Presenting Author: Masami Miki
Introduction: Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide phosphoribosyltransferase (NAMPT) and p21-activated kinase 4 (PAK4) could become a synthetic lethal strategy for PNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ph.D. Candidate Gabriel Mpilla